Tuberculosis (BCG) Vaccine Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Bill & Melinda Gates Medical Research Institute Initiates Phase 3 Clinical Trial of Tuberculosis Vaccine Candidate
CAMBRIDGE, Mass., March 19, 2024. The Bill& Melinda Gates Medical Research Institute (Gates MRI) today announced that a Phase 3 clinical trial to assess the efficacy of the M72/AS01E tuberculosis (TB) vaccine candidate is now underway, with... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 20, 2024 Category: Pharmaceuticals Source Type: clinical trials

Live Vaccines and Innate Immune Training in COPD.
Conditions: Trained Innate Immunity Interventions: Drug: BCG vaccine (Danish strain 1331); Drug: MMR Vaccine; Drug: Placebo Sponsors: Josefin Ekl öf Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 13, 2024 Category: Research Source Type: clinical trials

Antibiotics and Vaccine Immune Responses Study
Conditions: Vaccine Response Impaired Interventions: Biological: BCG vaccine; Biological: Yellow Fever vaccine; Drug: Vancomycin Oral Capsule; Drug: Neomycin Oral Product Sponsors: South Australian Health and Medical Research Institute; Royal Adelaide Hospital; Flinders University; University of Sydney; Telethon Kids Institute; Centenary Institute of Cancer Medicine and Cell Biology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 28, 2023 Category: Research Source Type: clinical trials

Does BCG Vaccination Reduce Biomarkers of Alzheimer's Disease?
Conditions: Alzheimer Disease, Late Onset Interventions: Biological: BCG vaccine Sponsors: Tamir Ben-Hur; Hebrew University of Jerusalem Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 12, 2023 Category: Research Source Type: clinical trials

Bacillus Calmette-Gu érin vaccination as defense against SARS-CoV-2 (BADAS): a randomized controlled trial to protect healthcare workers in the USA by enhanced trained immune responses
DiscussionIt is expected this trial will allow evaluation of the effects of BCG vaccination at a population level in high-risk healthcare individuals through a mitigated clinical course of SARS-CoV-2 infection and inform policy making during the ongoing epidemic.Trial registrationClinicalTrials.gov NCT04348370. Registered on April 16, 2020. (Source: Trials)
Source: Trials - October 4, 2023 Category: Research Source Type: clinical trials

First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107/CAF ®10b
Condition: Healthy Interventions: Biological: H107e; Biological: CAF®10b; Biological: H107e/CAF®10b - low adjuvant dose; Biological: H107e/CAF®10b - full adjuvant dose; Biological: Low dose intranasal H107e; Biological: Full dose intranasal H107e; Biological: H107e/CAF®10b; Biologica l: i.m. placebo; Biological: BCG; Biological: i.d. placebo; Biological: Intranasal H107e Sponsors: Statens Serum Institut; Aurum Institute; Bill and Melinda Gates Foundation; Leiden University Medical Center; South African Tuberculosis Vaccine Init...
Source: ClinicalTrials.gov - September 22, 2023 Category: Research Source Type: clinical trials

First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF ®10b
Condition: Healthy Interventions: Biological: H107e; Biological: CAF®10b; Biological: H107e/CAF®10b - low adjuvant dose; Biological: H107e/CAF®10b - full adjuvant dose; Biological: Low dose intranasal H107e; Biological: Full dose intranasal H107e; Biological: H107e/CAF®10b; Biologica l: i.m. placebo; Biological: BCG; Biological: i.d. placebo; Biological: Intranasal H107e Sponsors: Statens Serum Institut; Aurum Institute; Bill and Melinda Gates Foundation; Leiden University Medical Center; South African Tuberculosis Vaccine Init...
Source: ClinicalTrials.gov - September 22, 2023 Category: Research Source Type: clinical trials

First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF ®10b
Conditions: Healthy Interventions: Biological: H107e; Biological: CAF ®10b; Biological: H107e/CAF®10b - low adjuvant dose; Biological: H107e/CAF®10b - full adjuvant dose; Biological: Low dose intranasal H107e; Biological: Full dose intranasal H107e; Biological: H107e/CAF®10b; Biological: i.m. placebo; Biological: BCG; Biological: i.d. placebo; Biological: Intranas al H107e Sponsors: Statens Serum Institut; Aurum Institute; Bill and Melinda Gates Foundation; Leiden University Medical Center; South African Tuberculosis Vaccine Initiative Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 22, 2023 Category: Research Source Type: clinical trials

Using BCG Vaccine to Understand Tuberculosis Infection
Condition: Tuberculosis Intervention: Biological: Intradermal BCG (bacillus calmette-guerin) vaccine AJV Sponsors: Liverpool School of Tropical Medicine; University of Oxford Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2023 Category: Research Source Type: clinical trials